Walker Ex Rel. Aphton Corp. v. Sonafi Pasteur (In Re Aphton Corp.)

423 B.R. 76, 2010 Bankr. LEXIS 184, 2010 WL 308830
CourtUnited States Bankruptcy Court, D. Delaware
DecidedJanuary 27, 2010
Docket19-10267
StatusPublished
Cited by18 cases

This text of 423 B.R. 76 (Walker Ex Rel. Aphton Corp. v. Sonafi Pasteur (In Re Aphton Corp.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Walker Ex Rel. Aphton Corp. v. Sonafi Pasteur (In Re Aphton Corp.), 423 B.R. 76, 2010 Bankr. LEXIS 184, 2010 WL 308830 (Del. 2010).

Opinion

OPINION 1

CHRISTOPHER SONTCHI, Bankruptcy Judge.

INTRODUCTION

Before the Court are several motions brought by Sanofi Pasteur Limited (“SP”) and Aventis Pharmaceuticals, Inc. (“Aven-tis Pharmaceuticals”) (collectively, “Aven-tis”), 2 SF Capital Partners (“SF Capital”), Heartland Group, Inc., solely on behalf of the Heartland Value Fund and Heartland Value Fund, Inc. (collectively, “Heartland”), and Legg Mason Partners Fundamental Value Fund, Inc. f/k/a Smith Barney Fundamental Value Fund, Inc. (“Smith Barney”) (collectively, SF Capital, Heartland, and Smith Barney shall be referred to as the “Former Noteholders”).

The Former Noteholders and Aventis seek to dismiss the First Amended Complaint of Wayne Walker as Trustee of Aph-ton Corporation to Avoid and Recover Transfers Pursuant to 11 U.S.C. § 544, 548 and 550 (the “Complaint”). The Complaint contains six counts. 3 Counts I through III set forth constructive fraudulent conveyance claims against Aventis. Counts V through VII set forth constructive fraudulent conveyance claims against the Former Noteholders. Aventis and the Former Noteholders argue that the Complaint fails to state a claim upon which relief can be granted.

*81 The Former Noteholders have also filed a motion for sanctions pursuant to Federal Rule of Bankruptcy Procedure 9011. They argue that the actions of the Trustee’s counsel were objectively unreasonable in filing and maintaining the original complaint, and that the Trustee’s counsel took no action to dismiss voluntarily the original complaint or remedy its infirmities after being placed on notice of the Former Noteholders’ position.

For the reasons set forth below, the Court will (i) grant Aventis’s motion to dismiss; (ii) grant in part and deny in part the Former Noteholders’ motion to dismiss; and (iii) deny the motion for sanctions.

JURISDICTION

This Court has jurisdiction over this matter pursuant to 28 U.S.C. §§ 157 and 1334. Venue is proper in this district pursuant to 28 U.S.C. §§ 1408 and 1409. This is a core proceeding pursuant to 28 U.S.C. §§ 157(b)(2)(A), (F) and (H).

STATEMENT OF FACTS

A. Factual Background

i Parties To This Dispute

Aphton Corporation (the “Debtor”) is a biopharmaceutical company that researches, develops, and commercializes pharmaceutical products for the treatment of cancer and gastrointestinal disease. The Debtor filed a voluntary petition under Chapter 11 of the Bankruptcy Code in May, 2006.

Aventis Pharmaceuticals and SP are in the business of research, development and production of pharmaceuticals. The Complaint asserts that SP is “also known as” Aventis, although the motion to dismiss asserts that they are separate legal entities.

The Former Noteholders and the Debt- or were parties to a Purchase Agreement for certain notes. Per the agreement, the Former Noteholders paid the Debtor $15 million in exchange for the Debtor issuing notes that bore an equivalent face value.

ii. The Debtor’s Relationship With Aventis

In early 1997, the Debtor entered into a Co-Promotion Agreement and License (the “Co-Promotion Agreement”) with Connaught Laboratories Limited and its affiliated entities (collectively, “CLL”). 4 The Co-Promotion Agreement pertained to the Debtor’s development of a non-toxic immunotherapy drug, known as Insegia, designed to treat certain types of cancer, and the collaboration between the Debtor and Aventis in the co-promotion, marketing, selling and distribution of products being developed by the Debtor, including Insegia. The Co-Promotion Agreement also granted Aventis a non-exclusive license to manufacture the Debtor’s products and to have the Debtor’s products manufactured for it, while reserving the rights to promote, market, distribute and sell products on its own or in conjunction with Aventis.

Subsequent to the entry of the Co-Promotion Agreement, the Debtor and Aven-tis entered into two supply agreements (the “Supply Agreements”) that required (i) Aventis to supply the Debtor with certain biological materials necessary for the Debtor’s development of its products; and (ii) the Debtor to supply Aventis with the Debtor’s products.

In 2002, the Debtor and Aventis entered into an agreement to restructure the Co- *82 Promotion Agreement. 5 Under the restructuring agreement, the parties agreed to enter into a new co-promotion agreement under which the Debtor would grant Aventis an exclusive license related to the development, promotion, marketing, distribution or sale of any products. At the same time, the Debtor and Aventis entered into the Debenture Purchase Agreement in which the Debtor agreed to sell and Aventis agreed to purchase a convertible debenture in the principal amount of $3 million due December 19, 2007 (the “Debenture”).

In February, 2005, the Debtor announced that Insegia had failed to meet the clinical benchmarks necessary for FDA approval.

In a letter dated April 27, 2005, Aventis demanded that the Debtor pay $3 million and all accrued interest pursuant to the Debenture. Aventis asserted redemption was mandatory because (as revealed in the Debtor’s public filings) the Debtor had signed prohibited collaboration agreements. The Debtor redeemed the Debenture for $3 million in accordance with the terms of the Debenture Agreement (the “Redemption Payment”) on August 4, 2005.

On November 2, 2005, SP (as successor-in-interest to CLL) and the Debtor memorialized an agreement concerning termination (the “Termination Agreement”) of the Co-Promotion Agreement and the Supply Agreements. In the Termination Agreement, SP forgave a receivable due from the Debtor to SP for “conjugation services” in the amount of $1.8 million. The Termination Agreement contained a provision for the Debtor and SP to enter into a new supply agreement. It did not mention the Redemption Payment.

Hi The Debtor’s Relationship With The Former Noteholders

In March, 2003, the Debtor issued notes (the “Notes”) to the Former Noteholders.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Untitled Case
M.D. North Carolina, 2026
Brown v. Douglas
N.D. Texas, 2021
Aurzada v. Jenkins
N.D. Texas, 2020
Lee v. So
Superior Court of Delaware, 2016
Burtch v. Opus, LLC (In re Opus East, LLC)
528 B.R. 30 (D. Delaware, 2015)
Seitz v. 6130 West, LLC (In re Joey's Steakhouse, LLC)
474 B.R. 167 (E.D. Pennsylvania, 2012)
In Re Capmark Financial Group Inc.
438 B.R. 471 (D. Delaware, 2010)
Pryor v. Fisher (In Re Dimino)
429 B.R. 408 (E.D. New York, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
423 B.R. 76, 2010 Bankr. LEXIS 184, 2010 WL 308830, Counsel Stack Legal Research, https://law.counselstack.com/opinion/walker-ex-rel-aphton-corp-v-sonafi-pasteur-in-re-aphton-corp-deb-2010.